Drugs /

tak-164

Back to Drugs List

Overview

NCI Definition [1]:
An antibody-drug conjugate (ADC) comprised of a full-length, fully-human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against the extracellular domain of guanylyl cyclase C (GCC; GUCY2C), conjugated using the peptide-linked indolino-benzodiazepine DNA alkylator DGN549 (IGN-P1), with potential antineoplastic activity. Upon intravenous administration of TAK-164, the antibody moiety selectively binds to GCC-expressing cells. Upon antibody/antigen binding and internalization, the cytotoxic DGN549 payload is released and binds to guanine residues on opposing strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of GCC-expressing cells. GCC, a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain, is overexpressed on the surface of certain tumor cells.

Clinical Trials

View Clinical Trials for tak-164

Tak-164 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating tak-164, 1 is phase 1 (0 open).

GUCY2C Expression is the most frequent biomarker inclusion criterion for tak-164 clinical trials.

Digestive system carcinoma is the most common disease being investigated in tak-164 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Tak-164
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tak-164 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
tak164, tak 164, anti-gcc antibody-drug conjugate tak-164, anti-gcc adc tak-164
Drug Target(s) [2]:
GUCY2C
NCIT ID [1]:
C156707

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.